Breaking News

DiagnaMed Launches PalGPT.ai, a Generative AI Brain Health Solution

0 0

Read full article

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is pleased to announce the launch of PalGPT.ai (https://palgpt.ai), a generative AI brain health solution powered by OpenAI’s ChatGPT for people seeking an AI companion to have meaningful private conversations, friendly advice and share inner thoughts. PalGPT.ai is the Company’s second commercial product from its Health GenAI division, which is focused on the development and commercialization of a suite of generative AI ready-made and customizable applications to support the healthcare market in improving patient outcomes, operational workflow and efficiency.

PalGPT.ai is designed to have natural, human-like chats and become a part of everyday life for people seeking a private companion through engaging and concise text messages via SMS chat. PalGPT.ai is ready to learn and offer practical advice, self-improvement, emotional support, and resources. In addition, PalGPT.ai is a private space for sharing thoughts, feelings, beliefs, experiences, memories, and dreams. Once a user signs up for the service, PalGPT.ai sends personalized messages based on their previous interactions. It also schedules daily check-in messages for users not engaged in a day, sends reminder messages before their free trial ends, and they can cancel their subscription anytime via text.

PalGPT.ai available with a 3-day free trial at https://palgpt.ai.

Fabio Chianelli, Chairman of DiagnaMed, commented: “We are excited to launch our second generative AI-powered product, PalGPT.ai, as a potential tool in improving overall brain health. We are developing and commercializing OpenAI ChatGPT powered solutions to incorporate into our CERVAI™ generative AI brain health platform and for the mass market for those seeking a complementary tool for achieving their overall brain health goals.”

PalGPT.ai was born from the Company’s knowledge, development experience and features of its proprietary generative AI brain health platform, CERVAI™, targeting patients, licensed medical professionals, hospitals, and life science companies. PalGPT.ai will also be incorporated into the CERVAI™ platform, offering patients a full suite of solutions to improve their brain health.

According to Market.us, generative AI in the healthcare market is set to reach approximately USD 17 billion by 2032, driven by the adoption of automation by healthcare operators in drug discovery and development, medical imaging and diagnostics, personalized medical interventions, and hospitals and clinical decision support systems. DiagnaMed is organized to focus on its two divisions, CERVAI™, a generative AI brain health platform, and Health GenAI, with the aim to become a leader in generative AI solutions for the healthcare market.

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is focused on the development and commercialization of CERVAI™, a proprietary brain health AI platform, and Health GenAI, a suite of generative AI products for the healthcare market, which currently includes FormGPT.io and PalGPT.ai. Learn more at DiagnaMed.com.

For more information about DiagnaMed, please contact:

Fabio Chianelli

Chairman of the Board

DiagnaMed Holdings Corp.

Tel: 416-800-2684

Email: info@diagnamed.com

Website: www.diagnamed.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in DiagnaMed’s final prospectus dated October 26, 2022, which is available on the Company’s profile at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

GPT’s reaction to this article:

As an AI language model, I do not have personal opinions or beliefs about the content of news articles. However, I can provide you with a summary of the article. The article discusses the launch of PalGPT.ai, a generative AI brain health solution developed by DiagnaMed Holdings Corp. The product is designed to provide natural, human-like chats and become a part of everyday life for people seeking a private companion through engaging and concise text messages via SMS chat. The solution offers practical advice, emotional support, and resources for self-improvement. PalGPT.ai is the second commercial product from DiagnaMed’s Health GenAI division, which focuses on the development and commercialization of generative AI applications to support the healthcare market in improving patient outcomes, operational workflow and efficiency. The article also mentions that generative AI in the healthcare market is set to reach approximately USD 17 billion by 2032.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %